Artificial Intelligence & Machine Learning in Healthcare
AI Workforce Transformation & Education
Hematologic Malignancies (myelodysplastic syndromes/neoplasms, acut myleod leukemia, chronic myleomonocytic leukemia)
Genomic Prognostication & Precision Oncology
Personalized Predictive Modeling
AI in Drug Development
Aziz Nazha, MD
Adjunct Instructor
Adjunct Instructor
Research and Practice Interests
Education
MD, Tishreen University
Internal Medical Residency -
Thomas Jefferson University Affiliated /AtlantiCare Regional Medical Center
Leukemia Research Fellowship, The University of Texas MD Anderson Cancer Center
Hematology & Medical Oncology Fellowship, Cleveland Clinic Taussing Cancer Institute
Certifications
American Board of Internal Medicine
American Board of Hematology
American Board of Medical Oncology
BIOGRAPHY
Aziz Nazha, MD, is a physician-scientist and leader at the intersection of oncology and artificial intelligence (AI). As Executive Director of Jefferson Enterprise AI Workforce Transformation and Education at Thomas Jefferson University, Dr. Nazha leads institution-wide initiatives to prepare the healthcare workforce for the AI era, designing curriculum and programs that translate AI innovations into clinical and operational practice.
Dr. Nazha completed his medical degree at Tishreen University, followed by internal medicine residency training at Thomas Jefferson University Affiliated/AtlantiCare Regional Medical Center, a leukemia research fellowship at The University of Texas MD Anderson Cancer Center, and a hematology and medical oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. He subsequently joined the Cleveland Clinic faculty as Associate Staff and served as Director of the Center for Clinical Artificial Intelligence within Enterprise Analytics from 2019 to 2021.
Dr. Nazha’s research focuses on applying machine learning and AI to hematologic malignancies, particularly myelodysplastic syndromes/neoplasms (MDS/MN) and acute myeloid leukemia (AML). He has developed internationally validated personalized prediction models that integrate genomic and clinical data to risk-stratify patients, and has published more than 150 peer-reviewed articles in leading journals including Journal of Clinical Oncology, Blood, Nature Communications, and The Lancet Haematology. He is a recognized keynote speaker and international expert on AI in oncology.
Prior to joining Jefferson, Dr. Nazha held the role of Global Head of the AI Innovations Institute and Executive Director of Early Drug Development at Incyte Pharmaceuticals, and was a Global Tech Business Development Manager in Healthcare Solutions (Machine Learning/AI) at Amazon Web Services. He is board-certified in internal medicine, hematology, and medical oncology and is a member of the American Society of Hematology and the American Society of Clinical Oncology.